[Form 4] Akari Therapeutics plc ADR (0.01 USD) Insider Trading Activity

Rhea-AI Filing Summary

Akari Therapeutics plc (AKTX) insider Form 4: Gaslightwala Abizer, listed as both CEO and a director, reported multiple open-market purchases of the company’s American Depositary Shares in August 2025. Each American Depositary Share (ADS) represents 2,000 ordinary shares. On 08/21/2025 he acquired 10,000 ADS at a weighted average price of $0.94 increasing his holdings to 287,574 ADS. On 08/22/2025 he acquired 8,000 ADS at $0.93 (holdings: 295,574 ADS), and on 08/25/2025 he acquired 3,000 ADS at $0.90 (holdings: 298,574 ADS). The filing is signed by an attorney-in-fact on 08/29/2025.

Positive

• Insider accumulation: CEO and director purchased a total of 21,000 ADS across three open-market transactions in August 2025.
• Clear disclosure: Weighted average prices and post-transaction ADS holdings are provided for each purchase.
• Simple transactions: Only non-derivative purchases reported; no dispositions or derivative activity in this Form 4.

Negative

• None.

Insights

Securities Analyst

TL;DR: Insider purchases of AKTX ADS totaling 21,000 ADS across three dates, increasing reported holdings to 298,574 ADS.

The reported transactions show the CEO and director acquiring 10,000 ADS on 08/21/2025, 8,000 ADS on 08/22/2025 and 3,000 ADS on 08/25/2025 at weighted average prices of $0.94, $0.93 and $0.90 respectively. Each ADS represents 2,000 ordinary shares, as disclosed. These are open-market purchases reported on Form 4 and reflect additional insider accumulation without any derivatives reported.

Corporate Governance Expert

TL;DR: CEO/director disclosed multiple direct purchases of ADS in August 2025, filed via attorney-in-fact.

The filing identifies Gaslightwala Abizer as both CEO and a director and lists direct beneficial ownership increases. The Form 4 shows straightforward acquisitions with weighted average prices disclosed and an attorney-in-fact signature dated 08/29/2025. No options, grants, dispositions, or plan-based transactions are reported in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gaslightwala Abizer

(Last) (First) (Middle)

C/O AKARI THERAPEUTICS PLC

22 BOSTON WHARF ROAD FL 7

(Street)

BOSTON, MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Akari Therapeutics Plc [ AKTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares representing Ordinary Shares(1)	08/21/2025		P		10,000	A	$0.94(2)	287,574	D
American Depositary Shares representing Ordinary Shares(1)	08/22/2025		P		8,000	A	$0.93(3)	295,574	D
American Depositary Shares representing Ordinary Shares(1)	08/25/2025		P		3,000	A	$0.9(4)	298,574	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.

2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.93 to $0.94, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.92 to $0.93, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.89 to $0.90, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote.

	/s/ Torsten Hombeck, as Attorney-in-Fact	08/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Gaslightwala Abizer report on the AKTX Form 4?

He reported three open-market purchases: 10,000 ADS on 08/21/2025 at $0.94, 8,000 ADS on 08/22/2025 at $0.93, and 3,000 ADS on 08/25/2025 at $0.90.

How many Akari Therapeutics ADS does the reporting person own after these transactions?

The Form 4 reports post-transaction holdings of 287,574 ADS after 08/21, 295,574 ADS after 08/22, and 298,574 ADS after 08/25/2025.

What is the ADS-to-ordinary-share conversion for AKTX disclosed in the filing?

The filing states that 1 ADS represents 2,000 ordinary shares of the issuer.

Who signed the Form 4 and when was it signed?

The Form 4 is signed by /s/ Torsten Hombeck, as Attorney-in-Fact and dated 08/29/2025.

Does the Form 4 report any derivative transactions or dispositions?

No. Table II (derivatives) contains no reported transactions, and all entries in Table I are acquisitions (A).